Description
Tastylia (Tadalafil) 2.5 mg
Tastylia 2.5 mg contains tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor. Regulatory prescribing information for tadalafil identifies it as a medicine used for erectile dysfunction, and in some products and settings also for benign prostatic hyperplasia. The 2.5 mg strength is used as a once-daily tadalafil dose in approved labeling.
Active Ingredient and Medicine Class
Active ingredient: tadalafil.
Medicine class: PDE5 inhibitor.
Tadalafil is a selective inhibitor of PDE5, an enzyme involved in the breakdown of cyclic guanosine monophosphate (cGMP). By increasing cGMP activity in smooth muscle tissue, it supports blood vessel relaxation in the penis during sexual stimulation.
Established Medical Uses
Official tadalafil labeling confirms use for erectile dysfunction. Some approved tadalafil products also include benign prostatic hyperplasia and erectile dysfunction with benign prostatic hyperplasia. The specific 2.5 mg daily strength is included in prescribing information for once-daily erectile dysfunction use.
How It Works
Tadalafil helps enhance the natural erectile response to sexual stimulation by inhibiting PDE5 and preserving cGMP. This promotes smooth muscle relaxation and increased blood flow in erectile tissue. Its long duration of action is a well-described feature in clinical literature.
Important Safety Information
Tadalafil must not be used with nitrates or with guanylate cyclase stimulators such as riociguat, because of the risk of a marked drop in blood pressure. Prescribing information also warns about possible interactions with alpha-blockers, antihypertensives, potent CYP3A4 inhibitors, and substantial alcohol use. Tadalafil should be used cautiously in people with cardiovascular disease, low blood pressure risk, severe kidney or liver impairment, or conditions that may predispose to prolonged erection. It should not be combined with other PDE5 inhibitors or other erectile dysfunction therapies.
Possible Side Effects
Commonly reported adverse effects include headache, dyspepsia, back pain, myalgia, nasal congestion, dizziness, and flushing-related symptoms. More serious but uncommon reactions include prolonged erection or priapism, sudden vision loss, and sudden hearing loss. Rare hypersensitivity reactions have also been reported.
Scientific Evidence
PubMed-indexed reviews and meta-analyses support tadalafil as an effective PDE5 inhibitor for erectile dysfunction, with clinical benefit across different severities and etiologies. Published evidence also describes its long therapeutic window and tolerability profile, with headache, dyspepsia, back pain, nasal congestion, myalgia, and flushing among the most frequent adverse effects.
Medical Information Notice
This summary is for educational purposes only and is based on sources available at the time of review. It does not replace the official patient leaflet, product information, or assessment by a qualified healthcare professional.
Medical Sources
- DailyMed / FDA — Tadalafil tablets, Full Prescribing Information
- U.S. FDA — CIALIS (tadalafil) tablets, Prescribing Information
- Meuleman EJH et al. — Review of tadalafil in the treatment of erectile dysfunction. Expert Opin Pharmacother. 2003.
